Skip to main content

Table 3 Top somatically mutated genes in cancer susceptibility regions

From: Limited evidence that cancer susceptibility regions are preferential targets for somatic mutation

Cancer subtype First Second Third Fourth Fifth
Bladder FGFR3 (14.939) EPG5 (3.049) TP63 (2.744) GIGYF2 (2.439) MECOM (2.439)
Breast MAP3K1 (6.285) SYNE1 (4.773) BRCA2 (2.784) ZFHX4 (2.705) NOTCH2 (1.591)
Cervical COL11A2 (10.256) MED1 (10.256) EHMT2 (7.692) CDK12 (7.692) ABCF1 (5.128)
Colon HYDIN (11.161) RYR3 (9.821) MAP3K4 (7.143) IGF2R (6.696) MYO1B (5.804)
Endometrial ACACA (7.661) SYNRG (2.823) TADA2A (2.419) DUSP14 (1.613) C17orf78 (1.210)
Glioma (glioblastoma) EGFR (20.235) PLEKHG4B (1.760) CDKN2A (1.466) HELZ2 (1.466) SLC6A19 (1.173)
Glioma (low grade) EGFR (5.882) SLC6A3 (2.076) PLEKHG4B (1.384) SLC6A19 (1.384) KMT2A (1.384)
Kidney (chromophobe) ORAOV1 (1.515) PPFIA1 (1.515) SHANK2 (1.515) NA (−.---) NA (−.---)
Kidney (clear cell) ITPR2 (1.724) PPFIA1 (1.149) PRKCE (0.766) ZEB2 (0.766) EPAS1 (0.575)
Kidney (papillary) ITPR2 (3.571) PPFIA1 (2.381) PRKCE (1.190) ZEB2 (1.190) FGF3 (1.190)
Liver PIK3CD (1.938) KIF1B (1.938) CASZ1 (1.550) MYO1B (1.550) CLDN8 (1.550)
Lung (adenoma) NOTCH4 (6.509) TNXB (5.178) MDC1 (3.402) PLEKHG4B (3.254) ZBED9 (3.254)
Lung (small cell) ZBED9 (7.042) SLC17A2 (5.634) BRD9 (4.225) SLC6A19 (4.225) HIST1H2AA (4.225)
Lung (squamous) TNXB (5.618) SLC6A3 (5.056) LRRC16A (3.933) BTN2A2 (3.933) ZBED9 (3.933)
Multiple myeloma LTB (1.951) NEU1 (1.951) DNAH11 (1.951) TNXB (1.463) CACNA1I (1.463)
Ovarian (serous) CPAMD8 (1.899) UNC13A (1.266) MAST3 (1.266) HOXD10 (0.949) C10orf113 (0.949)
Ovarian (small) JAK3 (8.333) NA (−.---) NA (−.---) NA (−.---) NA (−.---)
Prostate SPOP (7.877) SYNE1 (3.425) RYR1 (2.397) TNXB (2.055) APOB (1.712)
Skin SORCS3 (14.082) CDKN2A (13.878) TRIOBP (11.224) ANKRD11 (8.571) AOX1 (8.367)
Stomach ZBTB20 (7.273) MROH2B (5.455) C6 (4.545) DRD3 (2.727) OXCT1 (2.727)
Thyroid TNS1 (0.748) TDRD7 (0.499) TBC1D2 (0.499) MBIP (0.499) NKX2-1 (0.499)
  1. Top gene name shown with percentage of samples mutated shown in parentheses
  2. NA no additional mutated genes for cancer subtype